Equity

Additional Paid-In Capital

Biogen Additional Paid-In Capital increased by 3.9% to $896.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 42.4%, from $629.90M to $896.70M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ1 2026

How to read this metric

An increase typically signals equity financing or the issuance of shares for employee compensation.

Detailed definition

This represents the amount of capital received from shareholders in excess of the par value of the common stock. It is g...

Peer comparison

High levels are common in growth-oriented tech companies that utilize stock-based compensation to attract talent.

Metric ID: additional_paid_in_capital

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$68.20M$119.00M$0.00$0.00$73.30M$91.20M$170.70M$242.20M$302.50M$329.50M$407.50M$488.50M$569.40M$629.90M$714.00M$797.70M$863.10M$896.70M
QoQ Change+74.5%-100.0%+24.4%+87.2%+41.9%+24.9%+8.9%+23.7%+19.9%+16.6%+10.6%+13.4%+11.7%+8.2%+3.9%
YoY Change+7.5%-23.4%+312.7%+261.3%+138.7%+101.7%+88.2%+91.2%+75.2%+63.3%+51.6%+42.4%
Range$0.00$896.70M
Avg YoY Growth+100.9%
Median YoY Growth+81.7%
Current Streak14+ quarters growth

Frequently Asked Questions

What is Biogen's additional paid-in capital?
Biogen (BIIB) reported additional paid-in capital of $896.70M in Q1 2026.
How has Biogen's additional paid-in capital changed year-over-year?
Biogen's additional paid-in capital increased by 42.4% year-over-year, from $629.90M to $896.70M.
What does additional paid-in capital mean?
Capital received from investors above the par value of the shares.